Davidson 2001a.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, parallel arm, flexible dose, double‐blind, multicentre, 1 week single‐blind placebo run‐in BLINDING Participants: Unclear Assessors: Unclear Administrators: Unclear ALLOCATION CONCEALMENT Method: Unclear RANDOMISATION Method: computer generated
Participants	SAMPLE Description: 208 DSM‐III‐R PTSD, 5% war trauma, mean age: 37.1 (18‐69), 78% male, duration of diagnosis: 12.3 years, 40% (83/208) MDD, baseline severity on CAPS‐2: sertraline (73.9) placebo (73.5) SCREENING Primary diagnosis: CAPS‐1, CAPS‐2 >= 50, minimum 6 months duration Comorbidity: None
Interventions	Description: sertraline 25 mg/d to between 50‐200 mg/d (avg: 146.3 mg/d) vs. placebo x 12 weeks
Outcomes	Primary outcomes: CAPS‐2, IES, CGI‐S, CGI‐I Secondary outcomes: DTS, HAM‐D, HAM‐A, PSQI Data estimation: LOCF (1 post‐baseline assessment)
Notes	INDUSTRY SUPPORT Industry funded: Yes Medication provided by industry: No Any of the authors work for industry: Yes ADDITIONAL INFORMATION Drop‐out rates: 30% on sertraline and 27% on placebo (not clear which sample was used as denominator) Quality rating score: 33
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear